Type 1 diabetes

The impact of insulin pump therapy compared to multiple daily injections on complications and mortality in type 1 diabetes: A real‐world retrospective cohort study

Diabetes Obes MetabPublished Retrospective cohort study

Main finding · All-cause mortalityResult — go to the resultRelative risk 0.716 95% CI 0.639–0.803

Authors' conclusion

Insulin pump therapy was associated with lower all-cause mortality and risk of diabetic ketoacidosis, but an increased risk of diabetic retinopathy compared with MDI. This result should be interpreted with caution due to potential differences in retinal screening frequency and subsequent bias.

Study context

Population
Adults with T1D, TriNetX global network of anonymised medical records; 5-year follow-up between January 2018 and March 202595,122 identified
Participants
17,124 vs 17,124
Exposure
Insulin pump therapy vs multiple daily injections (MDI)
  • Pumpn = 17,124
  • MDIn = 17,124reference
Outcome
All-cause mortality
Methodological detailsreal-world, propensity score matched, TriNetX platform
  • Real-world
  • Propensity score matched
  • TriNetX platform

Main finding

As reported in the abstract

Relative risk

0.716

95% CI 0.639–0.803

P < 0.001

Pumpvs MDI
RR 0.716 (95% CI 0.639–0.803); P < 0.001

Observational data: associations, not effects.

Further findings

OutcomeRR (95% CI)P value
DKA0.848 (0.786–0.915)P < 0.001
OutcomePumpMDI
Absolute reduction in HbA1c · five years−5.3 mmol/mol−4.5 mmol/mol
%−0.5%−0.4%

Absolute reduction in HbA1c · five years

Absolute reduction in HbA1c was comparable at five years

Safety

OutcomeRR (95% CI)P value
Diabetic retinopathy1.331 (1.247–1.420)P < 0.001

Original publication

The impact of insulin pump therapy compared to multiple daily injections on complications and mortality in type 1 diabetes: A real‐world retrospective cohort study. Diabetes Obes Metab. Published 19 May 2025. doi:10.1111/dom.16455

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.